Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Immunol Lett. 2017 Oct;190:201-205. doi: 10.1016/j.imlet.2017.08.018. Epub 2017 Aug 29.
Adoptive immunotherapy adopting chimeric antigen receptor (CAR) modified T cells has arisen attention as a hard-hitting therapy for numerous cancers. CARs are genetically engineered receptors that could stimulate tumor cytotoxicity once binding to the specific tumor epitopes. In spite of current noteworthy achievements in hematologic malignancies, the safety problems have aroused public awareness. In this review, we will focus on recent potential strategies to improve the security of CAR modified T cells.
嵌合抗原受体（CAR）修饰的 T 细胞过继免疫疗法作为一种针对多种癌症的有效治疗方法引起了广泛关注。CAR 是一种经过基因工程改造的受体，一旦与特定的肿瘤表位结合，就能够刺激肿瘤细胞的细胞毒性。尽管在血液恶性肿瘤方面取得了目前显著的成就，但安全性问题已经引起了公众的关注。在这篇综述中，我们将重点介绍最近一些可能的策略，以提高 CAR 修饰的 T 细胞的安全性。
